There are currently a number of LABA/LAMA fixed-dose combinations in development for COPD. 28 QVA149 (an inhaled fixed-dose combination comprising two 24-hr agents, the LABA indacaterol and the ...

A Comparison: LABA/ICS vs LABA/LAMA. In a 52-week trial, 3360 patients with moderate-to-severe COPD received either the twice-daily fixed-dose combination of salmeterol and fluticasone or the once ...

Recently, new fixed combinations of a LABA and a LAMA have become available. Two replicated phase 3 trials of one such combination have been performed and reported.

6 August2012, USA California (Acedrugstore.com): An experimental and novel lung medication with is a combination drug of LAMA/LABA and produced by GlaxoSmithKline and Theravance pharmaceutical compani ...

Among patients with COPD who complain of dyspnea or exercise intolerance, we recommend LABA/LAMA combination therapy over LABA or LAMA monotherapy (strong recommendation, moderate certainty evidence).

Using our insurer’s formulary as an example, ... have a lower average wholesale price. 13 The LAMA/LABA inhaler and ICS inhaler combination would also simplify future step-down to dual ...

GlaxoSmithKline's experimental once-daily lung drug LAMA/LABA showed positive results on Monday from late stage trials in patients with chronic obstructive pulmonary disease (COPD). The Phase III ...

Using a LABA in combination with a LAMA rather than an inhaled corticosteroid to treat COPD is more effective in preventing exacerbations, claim researchers. Patients receiving a combination of ...

SAN DIEGO — Patients who received a free or fixed-dose combination of a long-acting beta-agonist (LABA) and long-acting muscarinic antagonist (LAMA) experienced a lower risk for chronic ...

TAIPEI, Oct. 2, 2022 /PRNewswire/ -- AeroRx Therapeutics, LLC. (AeroRx) and HCmed Innovations Co., Ltd. (HCmed) have initiated a collaboration, introducing a LABA/LAMA combination solution for ...

Overall results demonstrated that for the LABA/LAMA cohort cardiovascular event frequency was 2.11% compared to 3.41% in the LABA/ICS cohort. Cerebrovascular event frequency was 0.42% for LABA ...

GSK and Theravance Announce Regulatory Submission for UMEC/VI (LAMA/LABA) in the US ANORO ELLIPTA(TM) Proposed Proprietary Name for UMEC/VI LONDON and SOUTH SAN FRANCISCO, CA -- (Marketwire) -- ...